China NMPA Approves TYVYT (sintilimab) In Combination With Chemotherapy For Gastric Cancer - Life Sciences, Biotechnology & Nanotechnology

On June 24, 2022, Innovent Biologics, Inc. and Eli Lilly and Company announced that the National Medical Products Administration (NMPA) of China approved the supplemental New Drug Application (sNDA) for...

Related Keywords

China ,Eli Lilly ,National Medical Products ,Innovent Biologics Inc ,Innovent Biologics ,New Drug ,Mondaq ,China Nmpa Approves Tyvyt Sintilimab In Combination With Chemotherapy For Gastric Cancer ,Food ,Drugs ,Healthcare ,Life Sciences ,Iotechnology Amp Nanotechnology , ,